IMP and Viral Vector manufacture

Viral Vector Core Facility 

The Viral Vector Core Facility (VVCF) has been producing recombinant viral vectors required by Oxford University Investigators for pre-clinical vaccine studies and other purposes for over a decade. The facility is also able to supply external academic and industrial collaborators subject to confirmation that there are no conflicts of interest with current research programmes.

Clinical BioManufacturing Facility

The Clinical BioManufacturing Facility has over 20 years’ experience producing biological Investigational Medicinal Products (IMPs) according to the principles of GMP for early phase clinical trials. CBF holds a Manufacturer’s Authorisation for Investigational Medicinal Products (MIA (IMPs)) from the Medicines and Healthcare products Regulatory Agency (MHRA), which allows it to manufacture a variety of products including viral vector and recombinant protein vaccines and advanced therapy medicinal products (ATMPs) such as cell and gene therapy products. All IMPs are manufactured and released in accordance with the European Clinical Trials Directive (2004). The facility can also import IMPs from outside the EU for use in clinical trials within the European Union.

Bioprocess & Analytical Development (BiPAD)

BiPAD can assist you in making sure your product if going to meet the good manufacturing practice (GMP) regulations required for producing medicines and using them in clinical trials. BiPAD is not a GMP manufacturing facility, instead it fills the gap between innovative laboratory research and GMP. BiPAD makes sure that the processes developed for manufacturing are GMP compliant, that validated analytical assays are in place, and that technology transfer to a GMP manufacturing facility is successful.